Leading oncology scientists in Brazil have just announced a major breakthrough in the fight against cancer.
A team of scientists at Universidade Federal do Rio Grande do Sul (UFRGS) has discovered that ivermectin nanoparticles destroy cancer cells, massively reducing tumors.
In a groundbreaking preclinical study, researchers led by Drs. Maiara Callegaro Velho and Ruy Carlos Ruver Beck showed that a nano-encapsulated form of ivermectin, when delivered intranasally, reduced glioma tumor volume in rats by over 70%.
The discovery is being hailed as a major development in the fight against glioblastoma, one of the deadliest forms of brain cancer.
This is the first study to investigate “nose-to-brain IVM delivery using nanotechnology,” the authors noted.
The team tested two ivermectin nanoformulations:
• IVM-NC: Ivermectin encapsulated in poly(ε-caprolactone) nano capsules
• IVM-MCM: Ivermectin within mesoporous silica particles
Only the IVM-NC formulation proved capable of crossing the blood-brain barrier and significantly reducing tumor size.
Rats received a tiny daily dose, just 60 μg/day, for 10 days via a non-invasive intranasal spray.
The result was a tumor shrinkage of more than 70%, along with healthier brain tissue, reduced swelling, and less abnormal blood vessel growth.
The treatment did not cause organ damage or lung toxicity.
These effects were observed at doses nearly 8 times lower than the amount approved for human antiparasitic use.
While ivermectin became a political flashpoint during the Covid pandemic, this study marks an exciting new breakthrough in oncology.
The study is rooted in science-based evidence with no exaggerations, leaving no room for establishment figures to dispute the findings.
The researchers emphasized the challenges of delivering therapeutics to the brain and how polymeric nano-carriers via intranasal delivery may finally offer a solution.
The scientists note that ivermectin’s bioavailability and inability to cross the blood-brain barrier have long hampered its cancer-fighting potential.
But nanoencapsulation may unlock the drug’s multi-target capabilities, especially against hard-to-treat brain tumors.
“This rigorously conducted study stays on an evidence-based science track,” the authors emphasized.
“The researchers avoided hyperbole, grounded the study in mechanistic oncology, and pursued a delivery route… with a growing track record in neurotherapeutics.”
This study signals a serious scientific breakthrough using a well-known, low-cost drug, repurposed in a novel nanoform.
Delivered non-invasively through the nose, ivermectin can be used to fight one of the most lethal cancers known to medicine.
The political noise around ivermectin has distracted from its emerging anticancer profile.
But if these findings hold in humans, intranasal nano-ivermectin could become one of the most accessible and revolutionary therapies for brain cancer in decades.
Further research is needed, but the science is too compelling to ignore.
